TAXOL® (paclitaxel) should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.
Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2 to 4% of patients receiving TAXOL in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and H2 antagonists. (See DOSAGE AND ADMINISTRATION.) Patients who experience severe hypersensitivity reactions to TAXOL should not be rechallenged with the drug.
TAXOL therapy should not be given to patients with solid tumors who have baseline neutrophil counts of less than 1500 cells/mm3 and should not be given to patients with AIDS-related Kaposi’s sarcoma if the baseline neutrophil count is less than 1000 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL.
TAXOL (paclitaxel) Injection is a clear colorless to slightly yellow viscous solution. It is supplied as a nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion.
TAXOL is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, TAXOL is indicated in combination with cisplatin.
TAXOL is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors. (See CLINICAL STUDIES: Breast Carcinoma.)
TAXOL is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
TAXOL, in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
TAXOL is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma.
Published Studies Related to Taxol (Paclitaxel)
Randomized, phase II, placebo-controlled, double-blind study with and without
enzastaurin in combination with paclitaxel and carboplatin as first-line
treatment followed by maintenance treatment in advanced ovarian cancer. 
diagnosed advanced ovarian cancer... CONCLUSION: The PCE combination increased PFS, but it was not significantly
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment
of human epidermal growth factor receptor 2-overexpressing metastatic breast
in patients with HER2-overexpressing metastatic breast cancer (MBC)... CONCLUSION: This trial demonstrated that lapatinib combined with paclitaxel
Final results of phase III SYMMETRY study: randomized, double-blind trial of
elesclomol plus paclitaxel versus paclitaxel alone as treatment for
chemotherapy-naive patients with advanced melanoma. 
with advanced melanoma... CONCLUSION: The addition of elesclomol to paclitaxel did not significantly
Phase III trial of carboplatin and paclitaxel with or without sorafenib in
metastatic melanoma. 
metastatic melanoma... CONCLUSION: Sorafenib does not improve OS when given in combination with CP for
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination
with carboplatin/paclitaxel versus placebo in combination with
carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to
platinum-based chemotherapy (AGO-OVAR 2.14). 
xenograft models of human ovarian cancer... CONCLUSIONS: Zibotentan 10mg/day plus carboplatin and paclitaxel did not result
Clinical Trials Related to Taxol (Paclitaxel)
Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma [Completed]
- To determine the maximum tolerated dose (MTD) of imatinib mesylate in combination with
fixed dose paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary
- To determine the nature and degree of toxicity of imatinib mesylate and paclitaxel in
this cohort of patients.
- To determine the efficacy of imatinib mesylate and paclitaxel in patients with stage
IIIC, IV or recurrent uterine papillary serous carcinoma whose tumor expresses either
c-Kit, PDGFR or abl.
Hepatic Arterial Infusion (HAI) of Abraxane [Active, not recruiting]
The goal of this clinical research study is find the highest tolerated dose of Abraxane
(nab-paclitaxel) that can be given directly into the liver of patients with advanced cancer
that has spread to the liver.
Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) [Completed]
Pazopanib will be given with TAXOL in one part, in another part pazopanib will be given with
TAXOL and PARAPLATIN, and in a third part pazopanib will be given with TAXOL and lapatinib
(patients separated in each part). Toxicity monitoring will enable us to find the largest
dose of pazopanib daily that can be safely given in combination with the chemotherapy agents
TAXOL and PARAPLATIN, and with lapatinib, as well as what side effects are likely to
manifest when these agents are given together and whether the combination of pazopanib with
chemotherapy, helps to treat different types of cancer. Another objective is to find out how
much pazopanib, TAXOL, PARAPLATIN and lapatinib are in the blood at specific times after the
agents are given. Collecting the blood samples requires that the patients remain in the
vicinity of the clinic overnight on 2 occasions.
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma [Active, not recruiting]
This is an open-label phase 1/2 study that will combine the chemotherapy agents gemcitabine
and nab-paclitaxel with an oral hedgehog inhibitor LDE225. The objective is to assess
tolerability and the resection rate of patients with borderline resectable pancreatic
adenocarcinoma who use this treatment.
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors [Recruiting]
The purpose of this study is to find out the good and bad effects that occur when BKM120 is
added to standard chemotherapy with carboplatin and paclitaxel.
Reports of Suspected Taxol (Paclitaxel) Side Effects
Febrile Neutropenia (54),
Asthenia (53), more >>
Page last updated: 2014-11-30